March 9, 2022

TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022

March 1, 2022

TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement

February 24, 2022

TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2

January 27, 2022

TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

December 21, 2021

TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients

December 6, 2021

TFF Pharmaceuticals Hosting Science Day on December 13, 2021

November 15, 2021

TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 8, 2021

TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

November 8, 2021

TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021

November 5, 2021

TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021